AstraZeneca halts share repurchases

Shares in drugs giant AstraZeneca were hit in afternoon trading on Monday after the company revealed that it has suspended its share repurchase programme.

After trading in the blue in morning trade, shares swung into negative territory shortly after the announcement, trading down 1.93% at 2,898p by 14:08.

The company has repurchased a net $0.7bn of shares since the end of the first half, bringing the year-to-date total to $2.3bn. The group's initial full-year target for repurchases stands at $4.5bn.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Chief Executive Officer Pascal Soriot, who was appointed as frontman of the pharmaceuticals mammoth on August 28th, said in a statement: "As I assume my new responsibilities at AstraZeneca, I believe this is a prudent step that maintains flexibility while the board and I complete the company's ongoing annual strategy update."

Nevertheless, the firm reassured that its core earnings per share (EPS) target range for the full year remains at $6.00-6.30.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.